Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,496.90
(
-1.44%
)
US TECH 100
23,031.80
(
-2.05%
)
Dow Jones
46,029.37
(
-0.86%
)
Brent Oil
102.06
(
3.32%
)
Bitcoin
68,388.56
(
-4.08%
)
News Focus
News Focus
Post# of 257293
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

mcbio

Send PM Follow Ignore
Followers 69
Posts 6152
Boards Moderated 0
Alias Born 11/26/2008

mcbio

Re: DewDiligence post# 164505

Thursday, 07/25/2013 9:57:51 PM

Thursday, July 25, 2013 9:57:51 PM

Post# of 257293

Insulin FoB’s are a mediocre business proposition, IMO. MNTA is not pursuing this market.

Biocon is pursuing generics of Lantus, Humalog, and Novolog, which collectively had 2012 net sales of $11.5B. How are potential generics of those three drugs a mediocre business proposition?
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today